As of today (2024-04-19), the Forward Annual Dividend Yield of Clinuvel Pharmaceuticals is 0.33%.
As of today (2024-04-19), the Trailing Annual Dividend Yield of Clinuvel Pharmaceuticals is 0.33%.
FRA:UR9's Forward Dividend Yield % is ranked worse than 89.33% of 150
companies
in the Biotechnology industry
Industry Median: 1.59
vs FRA:UR9: 0.33
Clinuvel Pharmaceuticals's Dividends per Share for the
six
months ended in Dec. 2023 was €0.03.
During the past 12 months, Clinuvel Pharmaceuticals's average Dividends Per Share Growth Rate was 25.00% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 17.00% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Clinuvel Pharmaceuticals was 17.00% per year. The lowest was 7.70% per year. And the median was 12.35% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Competitive Comparison
For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinuvel Pharmaceuticals Forward Dividend Yield % Distribution
For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Clinuvel Pharmaceuticals's Forward Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Clinuvel Pharmaceuticals Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
AUD 0.050
2023-09-05
2023-09-06
2023-09-20
Cash Dividend
annually
AUD:EUR 0.594682
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Clinuvel Pharmaceuticals's Forward Annual Dividend Yield (%) for Today is calculated as
Forward Annual Dividend Yield
=
Forward Full Year Dividend
/
Current Share Price
=
0.0297341
/
9.175
=
0.32 %
Current Share Price is €9.175.
Clinuvel Pharmaceuticals's Dividends per Share for the forward twelve months is calculated as €0.0297341 * 1 = €0.0297341.
Clinuvel Pharmaceuticals's Trailing Annual Dividend Yield (%) for Today is calculated as
Trailing Annual Dividend Yield
=
Most Recent Full Year Dividend
/
Current Share Price
=
0.0297341
/
9.175
=
0.32 %
Current Share Price is €9.175.
Clinuvel Pharmaceuticals's Dividends per Share for the trailing twelve months (TTM) ended in Today is €0.0297341.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Clinuvel Pharmaceuticals Forward Dividend Yield % Related Terms
Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Clinuvel Pharmaceuticals (FRA:UR9) Business Description
Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:UR9 has been successfully added to your